# Sidewinder Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sidewinder-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.sidewinderbio.com/
- Total disclosed funding: $137M
- Latest round: Series B (Apr 8, 2026)
- Investors on record: 9

## About

Based in San Diego founded by Eric Murphy, Sidewinder Therapeutics, Inc. focuses on developing next-generation bispecific antibody-drug conjugates for targeted cancer therapies, addressing unmet needs in oncology for patients with challenging solid tumors.Founded in 2023 and headquartered in San Diego, California, Sidewinder Therapeutics, Inc. specializes in the development of bispecific antibody-drug conjugates. The company has raised USD 137 mn in its latest funding round, SERIES B, which was completed on April 8, 2026. The funding round was co-led by Novartis Venture Fund and Frazier Healthcare Partners with participation from other investors including Alexandria Venture Investments and Goldman Sachs Asset Management. The firm has conducted 2 deals to date.Sidewinder Therapeutics specializes in the development of next-generation bispecific antibody-drug conjugates (ADCs) engineered to target receptor co-complexes on solid tumors. These agents aim to enhance tumor specificity and internalization, addressing significant unmet medical needs in oncology. Key markets targeted for these innovative treatment options include North America, Europe, and parts of Asia.Sidewinder Therapeutics intends to generate revenue through strategic partnerships and collaborations for advancing their bispecific ADCs into clinical development. Revenue will come from agreements with pharmaceutical companies and healthcare institutions, supported by milestone payments, licensing fees, and potential royalties from product commercialization.In April 2026, Sidewinder Therapeutics raised USD 137 mn in SERIES B funding to support the advancement of its bispecific ADC pipeline. The funding will facilitate IND preparation and submission for the lead asset, SWT012, and will advance multiple ADC programs for solid tumors through IND-enabling and early clinical development activities. The company plans to expand its reach into new markets, specifically targeting regions in Europe and Asia, by leveraging these financial resources.

## Funding rounds

- Series B, Apr 8, 2026, $137M — Frazier Healthcare Partners, Goldman Sachs Asset Management, OrbiMed Advisors, Novartis Venture Fund, Alexandria Venture Investments, Astellas Venture Management, Longwood Fund, DCVC, Samsara BioCapital
- Series A, Jun 30, 2023 — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B